John Erb

Non-Executive Chairman

John joined the board of the Company as an independent director and non-executive Chairman in June 2007. John has over 40 years of experience in the medical device industry. He is currently Chairman of the Board and Chief Executive Officer of CHF Solutions, Inc., a manufacturer of medical devices for the heart failure market. John previously served as Chairman of the Board for Vascular Solutions, Inc., manufacturer of medical devices for the cardiology and interventional radiology markets, which was acquired in 2017 by Teleflex, Inc. for US$1 billion. He has held numerous board positions, including CryoCath Technologies, Inc., acquired by Medtronic for US$350 million in 2008; and SenoRx, Inc., acquired by C.R. Bard for US$250 million in 2010. John has a bachelor’s degree in Business Administration from California State University, Fullerton.

Andy Jane

Non-Executive Director

Andy has more than 20 years of experience in the biomedical and IT industries. He is a Managing Director with Talu Ventures in Brisbane, Australia, with a portfolio of investments formerly managed by CM Capital Investments. Andy is a Board member of Piedmont Animal Health; Advent Pharmaceuticals Pty; Altiris Pharmaceuticals Inc.; and Piedmont Pharmaceuticals, Inc. He has a BSc Hons degree in Physics from the University of St Andrews in Scotland; a Master of Science degree in Instrumentation from the University of Manchester; a Diploma of Financial Services (Financial Markets) from AFMA; and a post-grad Certificate in Science Media & Journalism from the University of Technology in Sydney.

Sandra Lesenfants

Non-Executive Director

Sandra currently serves as the Vice President & General Manager of endoVenous business in the Medtronic Cardiac & Vascular Group. In her role, she is responsible for leading the development and global marketing of meaningful innovations and solutions to address chronic venous insufficiency, deep venous disease, and vascular embolization.

Sandra has broad commercial strategy experience and global business management skills from the vascular businesses at Medtronic, Covidien, EV3, and Siemens Healthcare. She has led several key integrations including the acquisition of Sapheon and its VenaSeal closure system, the integration of endoVenous business from Covidien’s Vascular Therapy business into Medtronic, and the integration of the embolization sales team from Medtronic’s Neurovascular division into endoVenous.

Sandra is on the Board of Directors of The American Venous Forum Foundation. She has a biomedical computer engineering degree from the University of Technology of Compiegne Engineering Institute in France.

Neville Mitchell

Non-Executive Director

Neville joined the board of the Company as an independent non-executive director in July 2012 and is the Chairman of the Audit and Risk Committee. Neville was CFO and Company Secretary of Cochlear Limited from 1995 to 2017. He is a non-executive Director of Sonic Healthcare (since 2108), Fisher and Paykel Healthcare (since 2018) and Q’Biotics (since 2017) . He is a member of the Australian Board of Taxation and a director of the South East Sydney Local Health District Board. Previously he served on the New South Wales Medical Devices Fund, was Chairman of the Group of 100 and Chairman Standing Committee (Accounting and Auditing)for ASIC. Neville has a Bachelor of Commerce Degree and is a member of Chartered Accountants Australia and New Zealand.

Chris Nave, Ph.D.

Non-Executive Director

Chris is a founding partner of Brandon Capital Partners and Chief Executive Officer of the Medical Research Commercialisation Fund.

Brandon Capital is a leading Australian life science investment firm with over $500M in assets currently under management.

Chris was previously Director of Commercialisation at the Baker IDI Heart and Diabetes Institute, Melbourne, Australia, where he led the commercialization of technologies developed at the Baker and Alfred Hospital. Chris was also Manager of the Biotechnology Team at Melbourne Ventures, the commercialisation company of the University of Melbourne.
In 2014, Chris was awarded the Australian Biotechnology Johnson & Johnson Industry Leadership Award, for his contribution to the industry.
Chris is currently a Director of Global Kinetics Corporation, PolyActiva, OccuRx Therapeutics, QueOncology and Athena Medicines. Chris has a first-class Honours degree in Science and a Ph.D. in Endocrinology and Physiology from the University of Melbourne and he has completed the Private Equity and Venture Capital Program at Harvard Business School, Boston, MA.